

Figure 1—Standard curve for fluorometric assay of aristolochic acid (●). Key: ▲, recovery from urine.

and phototube. The solutions were not freed from dissolved air. Measurements were made in 1-cm silica cells.

The following procedure was used. To 5 ml of a solution of aristolochic acid in 1% aqueous sodium bicarbonate (concentration range 0.05–0.5 µg/ml) in a 30-ml separator was added solid sodium hydrosulfite (10–20 mg). After 5 min, the solution was diluted with 5 ml of 1 M phosphate buffer (pH 7) and extracted with chloroform (5 ml). The extract was filtered through a small piece of cotton into a 10-ml volumetric flask. A second extraction was carried out with chloroform, and the two were combined in the volumetric flask and diluted to volume.

The reduction and extraction were found to be quantitative, as shown by UV spectrophotometry. The fluorescence spectrum of the extract was obtained with the excitation wavelength set at 340 nm. Depending on the settings for the emission slit, excitation slit, and reference and sample sensitivities, the overall sensitivity of the assay can vary. With median settings, linearity of response was observed in the concentration range of 0.05–0.5 µg/ml. It is necessary to set up a "standard curve" for each set of assays performed.

GLC—The assays were performed on a gas chromatograph<sup>6</sup> equipped with a flame-ionization detector. A glass U-shaped column (183 cm long and 0.63 cm o.d.) was packed with 3% SE 30 on 100–200-mesh column packing<sup>7</sup>, conditioned at 300° for 18 hr. Helium, the carrier gas, was maintained at 55 ml/min; the flow rate for hydrogen was 45 ml/min and that for air was 300 ml/min. The injector and detector were kept at 300°. The column oven temperature was maintained at 260°.

Procedure for Biological Samples—Urine samples (1–5 ml) containing aristolochic acid were extracted at pH 2–3 with chloro-




Figure 2—Standard curve for aristolochic acid.

<sup>6</sup> Varian model 2100 (Varian Aerograph, Walnut Creek, Calif.) equipped with a Varian Model A-25 strip-chart recorder.

<sup>7</sup> Varaport 30 from Varian Aerograph, Walnut Creek, Calif.

Table I—Recovery of Aristolochic Acid Added to Urine

Added, mg/ml	Recovered, mg/ml	Recovery, %
0.15	0.15	100
0.30	0.30	100
0.30	0.29	97
0.45	0.44	98

form (10 ml) in a 30-ml separator. The solvent layer was placed in a centrifuge tube and evaporated to dryness in a water bath (50°) under a gentle stream of air filtered through glass wool.

Derivatization—Trimethylanilinium hydroxide (9) (100 µl of 0.1 M) was added to the evaporated sample, and the volume was made up to 2 ml with methanol. Then 5 µl of this solution was injected into the gas chromatograph. Two injections were made for each sample. Under the conditions described, aristolochic acid emerged as a sharp peak at 9.7 min.

## RESULTS AND DISCUSSION

When the chloroform solutions of the aristololactam were excited at 340 nm, a characteristic emission spectrum with a maximum at 425 nm was obtained. Using this spectrum as the standard, quantitative recoveries of aristolochic acid were obtained at various concentrations (Fig. 1). Recovery of added aristolochic acid to urine is also shown in Fig. 1. Depending on the sensitivity settings used, the baseline of the fluorescence spectrum may vary and the standard curve may not pass through the origin. The deviation is usually slight, and the use of a standard curve with each batch of assays will compensate for it.

Three reducing agents were studied: stannous chloride, ammonium sulfide, and sodium hydrosulfite. Of these, stannous chloride requires acid conditions at which aristolochic acid has rather low solubility. Ammonium sulfide gave slow reduction. Sodium hydrosulfite gave the fastest reaction in a neutral medium.

The lactam showed much lower intensity of fluorescence in an aqueous medium, and interference from other biological constituents could cause problems. Hence, extraction with a solvent was considered necessary. Among the three solvents studied (ether, ethyl acetate, and chloroform), chloroform was the most convenient. Two extractions at pH 7 gave complete recovery of the lactam in the solvent layer.

The fluorometric assay is convenient and sensitive. With proper controls and higher sensitivity settings, concentrations of 0.02–0.05 µg/ml of aristolochic acid can be determined after reduction to the lactam.

For the GLC assay, a plot of the peak height versus the concentration is shown in Fig. 2. The minimum detectable concentration was 0.01 mg/ml (or 0.025 µg/5 µl injected.) By using a 2- or 5-ml sample, the limit can be lowered further.





Figure 3—Recovery of aristolochic acid from urine.




**Figure 4**—Gas chromatogram of aristolochic acid with the addition of trimethylanilinium hydroxide. (Aristolochic acid concentration = 0.4 mg/ml; attenuation,  $8 \times 10^{-11}$ . For other details, see text.)

Recovery of aristolochic acid added to urine is shown in Table I and Fig. 3. A blank was set up and processed the same way, and it gave no interfering peaks in the region of interest.

To confirm that the peak observed was due to the methyl ester, aristolochic acid was esterified with diazomethane and the authentic sample of the methyl ester was injected into the gas chromatograph. A peak with the same retention time (9.7 min) was observed. Figure 4 shows a typical chromatogram of aristolochic acid together with the minor component isolated from *A. clematitis*.

Since there is a possibility that aristolochic acid might undergo metabolic reduction and be excreted as the lactam, it was decided



**Figure 5**—Standard curve for reduced aristolochic acid (lactam).

to study the GLC characteristics of this compound. The lactam was prepared by the reduction of aristolochic acid with sodium hydrosulfite, and a standard curve was obtained in the usual manner (Fig. 5). The compound emerged as a sharp peak with a retention time of 3.0 min.

#### REFERENCES

- (1) S. M. Kupchan and R. W. Doskotch, *J. Med. Pharm. Chem.*, **5**, 657(1962).
- (2) L. Jackson, S. Kofman, A. Weiss, and H. Brodovsky, *Cancer Chemother. Rep.*, **42**, 35(1964).
- (3) M. Ivic, *Acta Fac. Med. Naissensis*, **1**, 29(1970).
- (4) G. J. Dammin, *Arch. Pathol.*, **93**, 372(1972).
- (5) K. Hideg, O. Henkowsky, and J. Metes, *Acta Physiol. Acad. Sci. Hung.*, **23**, 79(1963).
- (6) W. Schunack, E. Mutschler, and A. Rochelmeyer, *Pharmazie*, **20**, 685(1965).
- (7) L. Hruban and F. Santarg, *ibid.*, **20**, 357(1965).
- (8) R. T. Coutts, J. B. Stenlake, and W. D. Williams, *J. Chem. Soc.*, **1957**, 4120.
- (9) E. Brochmann-Hanssen and T. O. Oke, *J. Pharm. Sci.*, **58**, 370(1969).
- (10) M. Pailer and P. Bergthaller, *Monatsh. Chem.*, **96**, 863(1965).

#### ACKNOWLEDGMENTS AND ADDRESSES

Received March 25, 1974, from the College of Pharmacy, J. Hillis Miller Health Center, University of Florida, Gainesville, FL 32610

Accepted for publication September 13, 1974.

Supported in part by a grant from the Regional Medical Program Service, Department of Health, Education, and Welfare.

The authors acknowledge the helpful suggestions of Mr. Morton Robins, Director, Regional Medical Program Service.

\* To whom inquiries should be directed.